Russell Investments Group Ltd. Has $1.60 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Russell Investments Group Ltd. reduced its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 10.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,549 shares of the company’s stock after selling 5,474 shares during the quarter. Russell Investments Group Ltd. owned 0.08% of Harmony Biosciences worth $1,602,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of HRMY. GAMMA Investing LLC grew its holdings in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC grew its holdings in Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after acquiring an additional 965 shares during the period. KBC Group NV raised its position in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after acquiring an additional 819 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares during the period. Finally, Avanza Fonder AB bought a new stake in shares of Harmony Biosciences during the 4th quarter valued at about $145,000. 86.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on HRMY shares. Needham & Company LLC restated a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho lifted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $28.46 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The company has a market cap of $1.63 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.47 and a beta of 0.80. The firm has a 50-day moving average of $32.92 and a 200-day moving average of $34.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to analysts’ expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business’s revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 earnings per share. Equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sandip Kapadia sold 25,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Insiders sold 61,945 shares of company stock valued at $2,442,815 in the last three months. Company insiders own 23.60% of the company’s stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.